Spot Biosystems raised $40 million to advance the development of its clinical pipeline of extracellular vesicle-based nonviral gene therapies for the treatment of Duchenne muscular dystrophy and cardiac ischemia, including a first-in-human trial in DMD, a rare disorder.
